FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1817261750> ?p ?o ?g. }

• W1817261750 abstract "Background This is an updated version of the original Cochrane review published in Issue 3, 2012. That review considered both fibromyalgia and neuropathic pain, but the efficacy of milnacipran for neuropathic pain is now dealt with in a separate review. Milnacipran is a serotonin‐norepinephrine (noradrenaline) reuptake inhibitor (SNRI) that is licensed for the treatment of fibromyalgia in some countries, including Canada, Russia, and the United States. Objectives To assess the analgesic efficacy of milnacipran for pain in fibromyalgia in adults and the adverse events associated with its use in clinical trials. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE to 18 May 2015, together with reference lists of retrieved papers and reviews, and two clinical trial registries. For the earlier review, we also contacted the manufacturer. Selection criteria We included randomised, double‐blind studies of eight weeks' duration or longer, comparing milnacipran with placebo or another active treatment in fibromyalgia in adults. Data collection and analysis We extracted efficacy and adverse event data, and two review authors examined issues of study quality independently. Main results We identified one new study with 100 participants for the pooled analysis. We identified two additional reports of a study using an enriched enrolment randomised withdrawal (EERW) design that included participants from earlier randomised controlled trials and an open‐label study. Because this study used the same participants already included in our main analysis, and a different design, we dealt with it separately. The main analysis included six studies (five from the earlier review; 4238 participants in total), all of which were placebo‐controlled, and used titration to a target dose of milnacipran 100 or 200 mg, with assessment after 8 to 24 weeks of stable treatment. There were no studies with active comparators. Study quality was generally good, although the imputation method used in analyses of the primary outcomes could overestimate treatment effect. Both doses of milnacipran provided moderate levels of pain relief (at least 30% pain intensity reduction) to about 40% of participants treated, compared to 30% with placebo, giving a number needed to treat for an additional beneficial outcome (NNT) of 6 to 10 (high quality evidence). Using a stricter definition for responder and a more conservative method of analysis gave lower levels of response (while maintaining a 10% difference between milnacipran and placebo) and increased the NNT to 11 (high quality evidence). One EERW study was broadly supportive. Adverse events were common in both milnacipran (86%) and placebo (78%) groups (high quality evidence), but serious adverse events did not differ between groups (less than 2%) (low quality evidence). Nausea, constipation, and headache were the most common events showing the greatest difference between groups (number needed to treat for an additional harmful outcome (NNH) of 5.7 for nausea, 13 for constipation, and 29 for headache) (moderate quality evidence). Withdrawals for any reason were more common with milnacipran than placebo, and more common with 200 mg (NNH 9) than 100 mg (NNH 23), compared with placebo. This was largely driven by adverse event withdrawals, where the NNH compared with placebo was 14 for 100 mg and 7.0 for 200 mg (high quality evidence). Withdrawals due to lack of efficacy were less common with milnacipran than placebo but did not differ between doses (number needed to treat to prevent an additional unwanted outcome (NNTp) of 41) (moderate quality evidence). Authors' conclusions The evidence available indicates that milnacipran 100 mg or 200 mg is effective for a minority in the treatment of pain due to fibromyalgia, providing moderate levels of pain relief (at least 30%) to about 40% of participants, compared with about 30% with placebo. There were insufficient data to assess substantial levels of pain relief (at least 50%), and the use of last observation carried forward imputation may overestimate drug efficacy. Using stricter criteria for 'responder' and a more conservative method of analysis gave lower response rates (about 26% with milnacipran versus 17% with placebo). Milnacipran was associated with increased adverse events and adverse event withdrawals, which were significantly greater for the higher dose." @default.
• W1817261750 created "2016-06-24" @default.
• W1817261750 creator A5010590729 @default.
• W1817261750 creator A5017593126 @default.
• W1817261750 creator A5038998860 @default.
• W1817261750 creator A5049385540 @default.
• W1817261750 creator A5077191679 @default.
• W1817261750 date "2015-10-20" @default.
• W1817261750 modified "2023-10-03" @default.
• W1817261750 title "Milnacipran for pain in fibromyalgia in adults" @default.
• W1817261750 cites W1480729244 @default.
• W1817261750 cites W1496322206 @default.
• W1817261750 cites W1517417769 @default.
• W1817261750 cites W1582342156 @default.
• W1817261750 cites W1604347849 @default.
• W1817261750 cites W1655904958 @default.
• W1817261750 cites W1671027704 @default.
• W1817261750 cites W1814156287 @default.
• W1817261750 cites W1821125407 @default.
• W1817261750 cites W1822570906 @default.
• W1817261750 cites W1826161993 @default.
• W1817261750 cites W182755113 @default.
• W1817261750 cites W1873305365 @default.
• W1817261750 cites W1910061082 @default.
• W1817261750 cites W1943094646 @default.
• W1817261750 cites W1964065290 @default.
• W1817261750 cites W1970186596 @default.
• W1817261750 cites W1973637626 @default.
• W1817261750 cites W1973805158 @default.
• W1817261750 cites W1977521225 @default.
• W1817261750 cites W1982924223 @default.
• W1817261750 cites W1986215651 @default.
• W1817261750 cites W1993701541 @default.
• W1817261750 cites W1995021873 @default.
• W1817261750 cites W1997499592 @default.
• W1817261750 cites W2004343261 @default.
• W1817261750 cites W2004791658 @default.
• W1817261750 cites W2021630340 @default.
• W1817261750 cites W2024624938 @default.
• W1817261750 cites W2026544265 @default.
• W1817261750 cites W2033223166 @default.
• W1817261750 cites W2035602533 @default.
• W1817261750 cites W2036939301 @default.
• W1817261750 cites W2038693293 @default.
• W1817261750 cites W2040437210 @default.
• W1817261750 cites W2048800165 @default.
• W1817261750 cites W2049056319 @default.
• W1817261750 cites W2051471486 @default.
• W1817261750 cites W2052454787 @default.
• W1817261750 cites W2052631023 @default.
• W1817261750 cites W2063738853 @default.
• W1817261750 cites W2066589648 @default.
• W1817261750 cites W2068512721 @default.
• W1817261750 cites W2070284980 @default.
• W1817261750 cites W2072129911 @default.
• W1817261750 cites W2076962732 @default.
• W1817261750 cites W2081420353 @default.
• W1817261750 cites W2083355677 @default.
• W1817261750 cites W2084982638 @default.
• W1817261750 cites W2087508019 @default.
• W1817261750 cites W2091870595 @default.
• W1817261750 cites W2092480468 @default.
• W1817261750 cites W2103600429 @default.
• W1817261750 cites W2105525460 @default.
• W1817261750 cites W2107467149 @default.
• W1817261750 cites W2108344016 @default.
• W1817261750 cites W2109154846 @default.
• W1817261750 cites W2114702376 @default.
• W1817261750 cites W2114732854 @default.
• W1817261750 cites W2116446898 @default.
• W1817261750 cites W2117294447 @default.
• W1817261750 cites W2118171954 @default.
• W1817261750 cites W2127672027 @default.
• W1817261750 cites W2134516534 @default.
• W1817261750 cites W2141486538 @default.
• W1817261750 cites W2147398177 @default.
• W1817261750 cites W2149594634 @default.
• W1817261750 cites W2161344815 @default.
• W1817261750 cites W2253364553 @default.
• W1817261750 cites W2494623578 @default.
• W1817261750 cites W27094647 @default.
• W1817261750 cites W4234814399 @default.
• W1817261750 cites W4249032765 @default.
• W1817261750 cites W2595437246 @default.
• W1817261750 doi "https://doi.org/10.1002/14651858.cd008244.pub3" @default.
• W1817261750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6481368" @default.
• W1817261750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26482422" @default.
• W1817261750 hasPublicationYear "2015" @default.
• W1817261750 type Work @default.
• W1817261750 sameAs 1817261750 @default.
• W1817261750 citedByCount "43" @default.
• W1817261750 countsByYear W18172617502015 @default.
• W1817261750 countsByYear W18172617502016 @default.
• W1817261750 countsByYear W18172617502017 @default.
• W1817261750 countsByYear W18172617502018 @default.
• W1817261750 countsByYear W18172617502019 @default.
• W1817261750 countsByYear W18172617502020 @default.
• W1817261750 countsByYear W18172617502021 @default.
• W1817261750 countsByYear W18172617502022 @default.
• W1817261750 countsByYear W18172617502023 @default.

• next